In this work, we explored the matrisome gene expression profiles of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS) using publicly available RNA-seq data from The Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx) portal. A holistic, yet targeted, exploration of the tumor microenvironment is critical for better understanding the progression of gynecological cancers, identifying key biomarkers for cancer progression, establishing the role of gene expression in patient survival, and for assisting in the development of new targeted therapies. However, in the context of gynecological cancers, the matrisome has not been well characterized. Increasingly, the matrisome, a set of proteins that form the core of the extracellular matrix (ECM) or are closely associated with it, has been demonstrated to play a key role in tumor progression. (c) The Kaplan-Meier plot indicates that the discordant LUSC samples (bottom, yellow) have a worse recurrence free survival profile than the concordant LUSC samples (top, brown).
The discordant LUSC samples have a gene expression pattern weakly resembles LUAD. Column 4 is the Shedden gene expression signature where higher signature score (red) predicts poor overall survival in LUAD 8. Column 3 is tumor type by pathology, which is equivalent to the TCGA cohort. Column 2 is tumor's Pan-Cancer RNA subtype designation. (b) Column 1 is user custom annotation that partitions the samples into three groups: LUAD, concordant LUSC (where the cohort and the RNA subtype are consistent), and discordant LUSC (where the cohort and RNA subtype are inconsistent). (a) The heatmap shows gene expression for TCGA LUAD and LUSC samples in a combined lung cohort, over a set of genes differentially expressed (. | Using the UCSC Cancer Genomics Browser to compare lung cancer subtypes defined by pathology or Pan-Cancer RNAseq analysis and identify a subtype of discordant samples with poor recurrence free survival prognosis.
0 kommentar(er)
